Virtual Reality for Improving Pain and Distress in Patients With Advanced Stage Colorectal Cancer

2019 ◽  
Author(s):  
Keyword(s):  
Colorectal Cancer ◽  
Virtual Reality ◽  
Advanced Stage

scholarly journals YY1 Silencing Induces 5-Fluorouracil-Resistance and BCL2L15 Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance

2021 ◽  
Vol 22 (16) ◽  
pp. 8481
Author(s):  
Silvia Vivarelli ◽  
Luca Falzone ◽  
Saverio Candido ◽  
Benjamin Bonavida ◽  
Massimo Libra
Keyword(s):  
Colorectal Cancer ◽  
Response To Therapy ◽  
Advanced Stage ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Expression Levels ◽  
Single Cell Sequencing ◽  
Yin Yang 1 ◽  
Anti Cancer ◽  
Colorectal Cancer Cells

Colorectal cancer (CRC) is characterized by genetic heterogeneity and is often diagnosed at an advanced stage. Therefore, there is a need to identify novel predictive markers. Yin Yang 1 (YY1) is a transcription factor playing a dual role in cancer. The present study aimed to investigate whether YY1 expression levels influence CRC cell response to therapy and to identify the transcriptional targets involved. The diagnostic and prognostic values of YY1 and the identified factor(s) in CRC patients were also explored. Silencing of YY1 increased the resistance to 5-Fluorouracil-induced cytotoxicity in two out of four CRC cells with different genotypes. BCL2L15/Bfk pro-apoptotic factor was found selectively expressed in the responder CRC cells and downregulated upon YY1 knockdown. CRC dataset analyses corroborated a tumor-suppressive role for both YY1 and BCL2L15 whose expressions were inversely correlated with aggressiveness. CRC single-cell sequencing dataset analyses demonstrated higher co-expression levels of both YY1 and BCL2L15 within defined tumor cell clusters. Finally, elevated levels of YY1 and BCL2L15 in CRC patients were associated with larger relapse-free survival. Given their observed anti-cancer role, we propose YY1 and BCL2L15 as candidate diagnostic and prognostic CRC biomarkers.

Mo1621 - Association Between Time to Colonoscopy after a Positive Guaiac Fecal Test Result and Risk of Colorectal Cancer and Advanced Stage Disease at Diagnosis

2018 ◽  
Vol 154 (6) ◽  
pp. S-772-S-773
Author(s):  
Amani Beshara ◽  
Doron Comaneshter ◽  
Iris Dotan ◽  
Yaron Niv ◽  
Alexander Vilkin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Advanced Stage ◽  
Stage Disease ◽  
Test Result

Consuming “Innovation” in Tourism

2017 ◽  
pp. 215-232
Author(s):  
Azizul Hassan ◽  
Roya Rahimi
Keyword(s):  
Virtual Reality ◽  
Augmented Reality ◽  
Technological Innovation ◽  
Diffusion Of Innovations ◽  
Analytical Approach ◽  
Advanced Stage ◽  
Relevant Theory ◽  
Tourism Marketing ◽  
Tourism Product ◽  
Application Analysis

Upon understanding definition, features, application analysis of innovation and relevant theory of the Diffusion of Innovations, this study suggests Augmented Reality (AR) as a technological innovation. AR is an advanced stage of virtual reality that merges reality with computer simulated imageries in the real environment. This chapter synthesizes AR as an emerging and potential technology of digital tourism marketing and management. The aim of this analytical approach based chapter is to understand innovation from tourism product or services consumption perspective. Relevant evidences are also included on lenses of marketing, digitalization and innovation consumption. Results outline that, technology consumption is gradually reshaping and getting supported by the availability and accessibility of electronic formats as AR as a technological innovation. This symbolizes that the consumption of technological innovation as AR offers freedom to select, purchase and recommend in relation to the theory of Diffusion of Innovations by Rogers (1962).

Abstract B70: Race, age, and advanced stage colorectal cancer survival

2011 ◽  
Author(s):  
Kristin Wallace ◽  
Stephanie Oppenheimer ◽  
Marvella E. Ford ◽  
Grace Williamson ◽  
Anthony J. Alberg
Keyword(s):  
Colorectal Cancer ◽  
Cancer Survival ◽  
Advanced Stage ◽  
Colorectal Cancer Survival

scholarly journals Updates of colorectal cancer liver metastases therapy: review on DEBIRI

2020 ◽  
Vol 7 (1) ◽  
pp. HEP16 ◽  
Author(s):  
Giammaria Fiorentini ◽  
Donatella Sarti ◽  
Roberto Nani ◽  
Camillo Aliberti ◽  
Caterina Fiorentini ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Systemic Chemotherapy ◽  
Tumor Response ◽  
Public Health Issue ◽  
Advanced Stage ◽  
Stage At Diagnosis ◽  
Colorectal Cancer Liver Metastases ◽  
Safety And Efficacy ◽  
Metastatic Sites

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

scholarly journals Tumour–stroma ratio has poor prognostic value in non-pedunculated T1 colorectal cancer: A multi-centre case-cohort study

2020 ◽  
pp. 205064062097532
Author(s):  
Hao Dang ◽  
Gabi W van Pelt ◽  
Krijn JC Haasnoot ◽  
Yara Backes ◽  
Sjoerd G Elias ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Prognostic Value ◽  
Adverse Outcome ◽  
Advanced Stage ◽  
Tumour Stroma ◽  
Node Metastasis ◽  
Increased Risk ◽  
T1 Colorectal Cancer

Background Current risk stratification models for early invasive (T1) colorectal cancer are not able to discriminate accurately between prognostic favourable and unfavourable tumours, resulting in over-treatment of a large (>80%) proportion of T1 colorectal cancer patients. The tumour–stroma ratio (TSR), which is a measure for the relative amount of desmoplastic tumour stroma, is reported to be a strong independent prognostic factor in advanced-stage colorectal cancer, with a high stromal content being associated with worse prognosis and survival. We aimed to investigate whether the TSR predicts clinical outcome in patients with non-pedunculated T1 colorectal cancer. Methods Hematoxylin and eosin (H&E)-stained tumour tissue slides from a retrospective multi-centre case cohort of patients with non-pedunculated surgically treated T1 colorectal cancer were assessed for TSR by two independent observers who were blinded for clinical outcomes. The primary end point was adverse outcome, which was defined as the presence of lymph node metastasis in the resection specimen or colorectal cancer recurrence during follow-up. Results All 261 patients in the case cohort had H&E slides available for TSR scoring. Of these, 183 were scored as stroma-low, and 78 were scored as stroma-high. There was moderate inter-observer agreement (κ = 0.42). In total, 41 patients had lymph node metastasis, 17 patients had recurrent cancer and five had both. Stroma-high tumours were not associated with an increased risk for an adverse outcome (adjusted hazard ratio = 0.66, 95% confidence interval 0.37–1.18; p = 0.163). Conclusions Our study emphasises that existing prognosticators may not be simply extrapolated to T1 colorectal cancers, even though their prognostic value has been widely validated in more advanced-stage tumours.

Immunoblot analysis of c-Met expression in human colorectal cancer: Overexpression is associated with advanced stage cancer

2004 ◽  
Vol 21 (5) ◽  
pp. 409-417 ◽  
Author(s):  
Zhaoshi Zeng ◽  
Martin R Weiser ◽  
Matt D’Alessio ◽  
Andrew Grace ◽  
Jinru Shia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Immunoblot Analysis ◽  
Advanced Stage ◽  
Human Colorectal Cancer ◽  
Advanced Stage Cancer

Differences in survival for advanced-stage colorectal cancer (CRC) patients by lines of therapy received in a U.S. local oncology practice.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14106-e14106
Author(s):  
Susan H Foltz Boklage ◽  
Charles Kreilick ◽  
Carl V Asche ◽  
Sally Haislip ◽  
James W. Gilmore ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Proportional Hazards ◽  
Survival Rates ◽  
Cox Proportional Hazards ◽  
Advanced Stage ◽  
Line Treatment ◽  
Chemotherapy Drugs ◽  
Line Of Therapy ◽  
Oncology Practice

e14106 Background: Improvements in survival for advanced-stage colorectal cancer (CRC) patients who receive chemotherapy have been reported. We compared survival rates for patients with 3+ vs. <3 lines of therapy using electronic medical records of a local oncology practice in Georgia, USA. Methods: The Georgia Cancer Specialist (GCS) EMR Database (1/1/2005–07/ 31/2010) was used. The database contains data on patient demographics, cancer diagnostic information, chemotherapy and non-chemotherapy drugs administered written prescriptions, chemotherapy/radiation protocols, chemotherapy protocol changes, office visit information, and hospitalizations. Patients newly diagnosed with CRC between 01/01/05 and 06/31/10 treated with systemic therapy for CRC were identified. Patients were followed from initial CRC diagnosis to death, loss to follow-up, or end of study. Patients were categorized by number of lines of therapy received (1, 2, 3+) and original stage at diagnosis (III b/c, IV, unknown). Survival following initial line of therapy was evaluated using Cox proportional hazards models controlling forstage at diagnosis, type of 1st line treatment, and other patient characteristics. Results: The study included 704 patients with a median age of 63 years (age range 26-85 years) at diagnosis and 49% (n=345) female. 45% (n=317) and 42% (n=296) had stage IV and III b/c CRC at diagnosis, respectively. 53% (n=373) received only 1st line treatment, 27% (n=190) received 1st and 2nd line treatment and 20% (n=141) received 3rd line and beyond. The median follow up was 431 days and death was reported in 27%(n=190) of subjects. The multivariate Cox proportional hazard analysis indicated that there was no statistical difference in survival between patients who received 2nd line of therapy vs. 3 plus lines of therapy (HR=1.42; p<0.067). Conclusions: A non-statistical significant association between 2nd and more than 3 total lines of therapy in survival was found in subjects diagnosed with stage III B/C and IV. However the trend towards survival was present, indicating that some patients could benefit from the addition of 3rd line but it would require additional studies to confirm this.

Sign in / Sign up

Export Citation Format

Share Document